Salvatore Ulisse

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6019484/publications.pdf

Version: 2024-02-01

126 papers	4,187 citations	94433 37 h-index	138484 58 g-index
126 all docs	126 docs citations	126 times ranked	4943 citing authors

#	Article	IF	Citations
1	The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy. Current Cancer Drug Targets, 2009, 9, 32-71.	1.6	265
2	Thyroid Hormone and Male Gonadal Function*. Endocrine Reviews, 1995, 16, 443-459.	20.1	216
3	Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration. Kidney International, 2001, 60, 1097-1105.	5.2	204
4	Molecular basis of thyrotropin and thyroid hormone action during implantation and early development. Human Reproduction Update, 2014, 20, 884-904.	10.8	141
5	TSH Receptor and Thyroid-Specific Gene Expression in Human Skin. Journal of Investigative Dermatology, 2010, 130, 93-101.	0.7	100
6	Expression of Aurora kinases in human thyroid carcinoma cell lines and tissues. International Journal of Cancer, 2006, 119, 275-282.	5.1	94
7	Expression of Platelet-Derived Growth Factor-A (PDGF-A), PDGF-B, and PDGF Receptor-Î± and -Î² during Human Testicular Development and Disease. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2310-2319.	3.6	91
8	Fas and Fas Ligand Expression in Fetal and Adult Human Testis with Normal or Deranged Spermatogenesis. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2692-2700.	3.6	90
9	Trend in Thyroid Carcinoma Size, Age at Diagnosis, and Histology in a Retrospective Study of 500 Cases Diagnosed Over 20 Years. Thyroid, 2006, 16, 1151-1155.	4.5	85
10	Endorphins in male impotence: Evidence for naltrexone stimulation of erectile activity in patient therapy. Psychoneuroendocrinology, 1989, 14, 103-111.	2.7	81
11	Testicular development involves the spatiotemporal control of PDGFs and PDGF receptors gene expression and action.. Journal of Cell Biology, 1995, 131, 1105-1121.	5.2	81
12	Expression of Platelet-Derived Growth Factor-A (PDGF-A), PDGF-B, and PDGF Receptor-Â and -Â during Human Testicular Development and Disease. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2310-2319.	3.6	78
13	Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies. International Journal of Molecular Sciences, 2019, 20, 2560.	4.1	72
14	Thyroid hormone stimulates glucose transport and GLUT1 mRNA in rat Sertoli cells. Molecular and Cellular Endocrinology, 1992, 87, 131-137.	3.2	65
15	Q-Elastography in the Presurgical Diagnosis of Thyroid Nodules with Indeterminate Cytology. PLoS ONE, 2012, 7, e50725.	2.5	63
16	Apoptotic Effects of Selected Strains of Lactic Acid Bacteria on a Human T Leukemia Cell Line Are Associated With Bacterial Arginine Deiminase and/or Sphingomyelinase Activities. Nutrition and Cancer, 2001, 40, 185-196.	2.0	58
17	Developmental regulation of the thyroid hormone receptor alpha 1 mRNA expression in the rat testis. Molecular Endocrinology, 1994, 8, 89-96.	3.7	58
18	Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines. Endocrine-Related Cancer, 2008, 15, 559-568.	3.1	57

#	Article	IF	Citations
19	Papillary Thyroid Cancer Prognosis: An Evolving Field. Cancers, 2021, 13, 5567.	3.7	57
20	Fas expression correlates with human germ cell degeneration in meiotic and post-meiotic arrest of spermatogenesis. Molecular Human Reproduction, 2002, 8, 213-220.	2.8	55
21	Prevalence, Mass, and Glucose-Uptake Activity of 18F-FDG-Detected Brown Adipose Tissue in Humans Living in a Temperate Zone of Italy. PLoS ONE, 2013, 8, e63391.	2.5	55
22	Molecular Targeted Therapies of Aggressive Thyroid Cancer. Frontiers in Endocrinology, 2015, 6, 176.	3.5	54
23	Association of epicardial fat thickness with the severity of obstructive sleep apnea in obese patients. International Journal of Cardiology, 2013, 167, 2244-2249.	1.7	52
24	Natural killer cells and nitric oxide. International Immunopharmacology, 2001, 1, 1513-1524.	3.8	49
25	Sorafenib and Thyroid Cancer. BioDrugs, 2013, 27, 615-628.	4.6	48
26	Comparison of Malignancy Rate in Thyroid Nodules with Cytology of Indeterminate Follicular or Indeterminate HÃ¼rthle Cell Neoplasm. Thyroid, 2009, 19, 355-360.	4.5	47
27	Transforming acidic coiled-coil 3 and Aurora-A interact in human thyrocytes and their expression is deregulated in thyroid cancer tissues. Endocrine-Related Cancer, 2007, 14, 827-837.	3.1	46
28	Iodine deficiency in pregnant women residing in an area with adequate iodine intake. Nutrition, 2008, 24, 458-461.	2.4	45
29	Ciona intestinalis nuclear receptor 1: A member of steroid/thyroid hormone receptor family. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 11152-11157.	7.1	44
30	Molecular testing in the diagnosis of differentiated thyroid carcinomas. Gland Surgery, 2018, 7, S19-S29.	1.1	44
31	High Expression of the Urokinase Plasminogen Activator and Its Cognate Receptor Associates with Advanced Stages and Reduced Disease-Free Interval in Papillary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 504-508.	3.6	43
32	Prevalence of breast cancer in thyroid diseases: results of a cross-sectional study of 3,921 patients. Breast Cancer Research and Treatment, 2014, 144, 683-688.	2.5	42
33	Thyroid Imaging Reporting and Data System Score Combined with the New Italian Classification for Thyroid Cytology Improves the Clinical Management of Indeterminate Nodules. International Journal of Endocrinology, 2017, 2017, 1-8.	1.5	42
34	Iodine: Its Role in Thyroid Hormone Biosynthesis and Beyond. Nutrients, 2021, 13, 4469.	4.1	42
35	Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas. European Journal of Cancer, 2006, 42, 2631-2638.	2.8	40
36	Cervical lymph node metastases from thyroid cancer: does thyroglobulin and calcitonin measurement in fine needle aspirates improve the diagnostic value of cytology?. BMC Clinical Pathology, 2013, 13, 7.	1.8	39

#	Article	IF	Citations
37	Thyroid hormone and glucocorticoid independently regulate the expression of estrogen receptor in male Xenopus liver cells. Molecular and Cellular Endocrinology, 1994, 105, 45-53.	3.2	38
38	Severe oligozoospermia in a young man with chronic myeloid leukemia on long-term treatment with imatinib started before puberty. Fertility and Sterility, 2011, 95, 1120.e15-1120.e17.	1.0	38
39	In papillary thyroid carcinoma <scp>BRAF</scp>^{V600E} is associated with increased expression of the urokinase plasminogen activator â€¨and its cognate receptor, but not with diseaseâ€free interval. Clinical Endocrinology, 2012, 77, 780-786.	2.4	38
40	Vitiligo and Autoimmune Thyroid Disorders. Frontiers in Endocrinology, 2017, 8, 290.	3.5	38
41	Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo. Oncology Reports, 2018, 39, 2225-2234.	2.6	38
42	Decorin counteracts disease progression in mice with recessive dystrophic epidermolysis bullosa. Matrix Biology, 2019, 81, 3-16.	3.6	38
43	Low Serum Bioactive Luteinizing Hormone In Nonorganic Male Impotence: Possible Relationship with Altered Gonadotropin-Releasing Hormone Pulsatility. Journal of Clinical Endocrinology and Metabolism, 1988, 67, 867-875.	3.6	36
44	PD-1 Ligand Expression in Epithelial Thyroid Cancers: Potential Clinical Implications. International Journal of Molecular Sciences, 2019, 20, 1405.	4.1	36
45	Dominant-negative mutant thyroid hormone receptors prevent transcription from Xenopus thyroid hormone receptor beta gene promoter in response to thyroid hormone in Xenopus tadpoles in vivo.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 1205-1209.	7.1	34
46	Sella Turcica Atypical Teratoid/Rhabdoid Tumor Complicated with Lung Metastasis in an Adult Female. Clinical Medicine Insights: Case Reports, 2013, 6, CCRep.S12834.	0.7	34
47	Erk-dependent cytosolic phospholipase A2 activity is induced by CD95 ligand cross-linking in the mouse derived Sertoli cell line TM4 and is required to trigger apoptosis in CD95 bearing cells. Cell Death and Differentiation, 2000, 7, 916-924.	11.2	33
48	Follicle-Stimulating Hormone-Induced Phospholipase A2 Activity and Eicosanoid Generation in Rat Sertoli Cells1. Biology of Reproduction, 1994, 51, 140-145.	2.7	31
49	Regulation by Thyroid Hormone of the Expression of Basement Membrane Components in Rat Prepubertal Sertoli Cells1. Endocrinology, 1998, 139, 741-747.	2.8	31
50	Fas and Fas Ligand Expression in Fetal and Adult Human Testis with Normal or Deranged Spermatogenesis. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2692-2700.	3.6	30
51	Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) and PACAP-Receptor Type 1 Expression in Rat and Human Placenta1. Endocrinology, 2000, 141, 1158-1167.	2.8	29
52	Association of Thyroid Diseases with Primary Extra-Thyroidal Malignancies in Women: Results of a Cross-Sectional Study of 6,386 Patients. PLoS ONE, 2015, 10, e0122958.	2.5	29
53	New Targeted Therapies for Anaplastic Thyroid Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2012, 12, 87-93.	1.7	28
54	Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines. Endocrine-Related Cancer, 2014, 21, 797-811.	3.1	28

#	Article	IF	Citations
55	Deregulated Expression of Aurora Kinases Is Not a Prognostic Biomarker in Papillary Thyroid Cancer Patients. PLoS ONE, 2015, 10, e0121514.	2.5	27
56	Aurora-C interacts with and phosphorylates the transforming acidic coiled-coil 1 protein. Biochemical and Biophysical Research Communications, 2011, 408, 647-653.	2.1	26
57	Analysis of clinical, ultrasound and colour flowâ€Doppler characteristics in predicting malignancy in follicular thyroid neoplasms. Clinical Endocrinology, 2008, 69, 342-344.	2.4	25
58	Aurora kinases are expressed in medullary thyroid carcinoma (MTC) and their inhibition suppresses in vitro growth and tumorigenicity of the MTC derived cell line TT. BMC Cancer, 2011, 11, 411.	2.6	25
59	Thyroid hormone regulates protease expression and activation of Notch signaling in implantation and embryo development. Journal of Endocrinology, 2018, 236, 1-12.	2.6	25
60	Iodine deficiency in pregnancy: Still a health issue for the women of Cassino city, Italy. Nutrition, 2018, 50, 60-65.	2.4	23
61	The combination of RAF265, SB590885, ZSTK474 on thyroid cancer cell lines deeply impact on proliferation and MAPK and PI3K/Akt signaling pathways. Investigational New Drugs, 2014, 32, 626-635.	2.6	22
62	Thyroid diseases and skin autoimmunity. Reviews in Endocrine and Metabolic Disorders, 2018, 19, 311-323.	5.7	22
63	CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo. Molecular and Cellular Endocrinology, 2014, 393, 56-64.	3.2	21
64	Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo. Oncology Reports, 2018, 39, 2306-2314.	2.6	21
65	CTLA-4 and PD-1 Ligand Gene Expression in Epithelial Thyroid Cancers. International Journal of Endocrinology, 2018, 2018, 1-10.	1.5	20
66	Antineoplastic Effects of PPAR? Agonists, with a Special Focus on Thyroid Cancer. Current Medicinal Chemistry, 2016, 23, 636-649.	2.4	20
67	LH action in the leydig cell: Modulation by angiotensin II and corticotropin releasing hormone, and regulation of P45017l± mRNA. The Journal of Steroid Biochemistry, 1989, 34, 205-217.	1.1	19
68	The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer. Expert Review of Anticancer Therapy, 2016, 16, 1109-1118.	2.4	19
69	Antineoplastic Effect of Lenvatinib and Vandetanib in Primary Anaplastic Thyroid Cancer Cells Obtained From Biopsy or Fine Needle Aspiration. Frontiers in Endocrinology, 2018, 9, 764.	3.5	19
70	The iodine nutritional status in the Italian population: data from the Italian National Observatory for Monitoring Iodine Prophylaxis (OSNAMI) (period 2015â€“2019). American Journal of Clinical Nutrition, 2019, 110, 1265-1266.	4.7	19
71	Expression and Clinical Utility of Transcription Factors Involved in Epithelialâ€“Mesenchymal Transition during Thyroid Cancer Progression. Journal of Clinical Medicine, 2021, 10, 4076.	2.4	19
72	Ontogenesis and cell specific localization of Fas ligand expression in the rat testis. Journal of Developmental and Physical Disabilities, 2004, 27, 304-310.	3.6	18

#	Article	IF	Citations
73	Deregulation of Aurora kinase gene expression in human testicular germ cell tumours. Andrologia, 2010, 42, 260-267.	2.1	18
74	Evaluation of Clinicopathological and Molecular Parameters on Disease Recurrence of Papillary Thyroid Cancer Patient: A Retrospective Observational Study. Cancers, 2020, 12, 3637.	3.7	18
75	Emerging molecular markers for the prognosis of differentiated thyroid cancer patients. International Journal of Surgery, 2014, 12, S52-S56.	2.7	17
76	Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer. Mini-Reviews in Medicinal Chemistry, 2015, 16, 86-93.	2.4	17
77	Sorafenib in the treatment of thyroid cancer. Expert Review of Anticancer Therapy, 2015, 15, 863-874.	2.4	17
78	Follicle-stimulating hormone increases the expression of tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2 and induces TIMP-1 AP-1 site binding complex(es) in prepubertal rat Sertoli cells. Endocrinology, 1994, 135, 2479-2487.	2.8	17
79	A Mathematical Formula to Estimate In Vivo Thyroid Volume from Two-Dimensional Ultrasonography. Thyroid, 2008, 18, 879-882.	4.5	16
80	Thyroid Diseases and Breast Cancer. Journal of Personalized Medicine, 2022, 12, 156.	2.5	16
81	IDENTIFICATION OF IMMUNOREACTIVE GASTRIN-RELEASING PEPTIDE RELATED SUBSTANCES IN ADULT RAT LEYDIG CELLS. Endocrinology, 1989, 124, 558-560.	2.8	15
82	A New Aurora in Anaplastic Thyroid Cancer Therapy. International Journal of Endocrinology, 2014, 2014, 1-11.	1.5	15
83	Aggressive thyroid cancer: targeted therapy with sorafenib. Minerva Endocrinology, 2017, 42, 64-76.	1.1	15
84	Increased expression of urokinase plasminogen activator and its cognate receptor in human seminomas. BMC Cancer, 2010, 10, 151.	2.6	14
85	CCL2 is Modulated by Cytokines and PPAR-Î³ in Anaplastic Thyroid Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2018, 18, 458-466.	1.7	14
86	The aurora kinase inhibitor VX-680 shows anti-cancer effects in primary metastatic cells and the SW13 cell line. Investigational New Drugs, 2016, 34, 531-540.	2.6	13
87	Novel treatment options for anaplastic thyroid cancer. Expert Review of Endocrinology and Metabolism, 2017, 12, 279-288.	2.4	13
88	Induction of Apoptosis by 1,4-Benzothiazine Analogs in Mouse Thymocytes. Journal of Pharmacology and Experimental Therapeutics, 2002, 300, 1053-1062.	2.5	12
89	Differential responses to ligands of overexpressed thyroid hormone and retinoid X receptors in a Xenopus cell line and in vivo. Molecular and Cellular Endocrinology, 1997, 126, 17-24.	3.2	11
90	Consumption of iodized salt may not represent a reliable indicator of iodine adequacy: Evidence from a cross-sectional study on schoolchildren living in an urban area of central Italy. Nutrition, 2016, 32, 662-666.	2.4	11

#	Article	IF	Citations
91	Inhibition of the aurora kinases suppresses in vitro NT2-D1 cell growth and tumorigenicity. Journal of Endocrinology, 2010, 204, 135-142.	2.6	10
92	Iodine Status in Schoolchildren and Pregnant Women of Lazio, a Central Region of Italy. Nutrients, 2019, 11, 1647.	4.1	10
93	Deregulated expression of VHL mRNA variants in papillary thyroid cancer. Molecular and Cellular Endocrinology, 2017, 443, 121-127.	3.2	9
94	Early thyroid hormone treatment in rats increases testis size and germ cell number. Endocrinology, 1993, 132, 2726-2728.	2.8	9
95	In Vitro and In Vivo Effects of the Urokinase Plasminogen Activator Inhibitor WX-340 on Anaplastic Thyroid Cancer Cell Lines. International Journal of Molecular Sciences, 2022, 23, 3724.	4.1	9
96	Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer. International Journal of Molecular Sciences, 2022, 23, 5731.	4.1	9
97	High Levels of Circulating Chemokine (C-X-C motif) Ligand 11 Are Associated with Euthyroid or Subclinically Hypothyroid Autoimmune Thyroiditis and with Chemokine (C-X-C Motif) Ligand 10. Journal of Interferon and Cytokine Research, 2012, 32, 74-80.	1.2	8
98	Preclinical testing of selective Aurora kinase inhibitors on a medullary thyroid carcinoma-derived cell line. Endocrine, 2016, 52, 287-295.	2.3	8
99	New perspectives in the diagnosis of thyroid follicular lesions. International Journal of Surgery, 2017, 41, S7-S12.	2.7	8
100	Nodular thyroid disease in the elderly: novel molecular approaches for the diagnosis of malignancy. Aging Clinical and Experimental Research, 2017, 29, 7-13.	2.9	8
101	Regulation by Thyroid Hormone of the Expression of Basement Membrane Components in Rat Prepubertal Sertoli Cells. Endocrinology, 1998, 139, 741-747.	2.8	8
102	Expression and prognostic value of the cell polarity PAR complex members in thyroid cancer. International Journal of Oncology, 2017, 50, 1413-1422.	3.3	7
103	Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) and PACAP-Receptor Type 1 Expression in Rat and Human Placenta. Endocrinology, 2000, 141, 1158-1167.	2.8	7
104	Expression of Fas and Fas ligand in human testicular germ cell tumours. Journal of Developmental and Physical Disabilities, 2009, 32, 123-130.	3.6	6
105	Virilizing Leydig-Sertoli Cell Ovarian Tumor Associated with Endometrioid Carcinoma of the Endometrium in a Postmenopausal Patient: Case Report and General Considerations. Clinical Medicine Insights: Case Reports, 2012, 5, CCRep.S10555.	0.7	6
106	Tyrosine kinase inhibitors for the therapy of anaplastic thyroid cancer. International Journal of Endocrine Oncology, 2015, 2, 135-142.	0.4	6
107	Dysregulation of microRNA expression in diabetic skin. Journal of Dermatological Science, 2020, 98, 186-194.	1.9	5
108	Advances in pharmacotherapy for advanced thyroid cancer of follicular origin (PTC, FTC). New approved drugs and future therapies. Expert Opinion on Pharmacotherapy, 2022, 23, 599-610.	1.8	5

#	Article	IF	Citations
109	Effects of Ultraviolet Radiation on FRTL-5 Cell Growth and Thyroid-Specific Gene Expression. Astrobiology, 2013, 13, 536-542.	3.0	4
110	Solid Cancer Treatment With Aurora Kinase Inhibitors: Towards a Personalized Medicine. EBioMedicine, 2017, 25, 18-19.	6.1	4
111	Selective embolization of the thyroid arteries (SETA): Ten years' experience. Asian Journal of Surgery, 2019, 42, 847-848.	0.4	4
112	Early discharge after total thyroidectomy: a retrospective feasibility study. Giornale Di Chirurgia, 2016, 27, 250.	0.2	4
113	Minimally invasive video-assisted thyroidectomy and transoral video-assisted thyroidectomy: A comparison of two systematic reviews. Journal of Minimal Access Surgery, 2020, 16, 315.	0.7	4
114	Circulating SIRT1 and Sclerostin Correlates with Bone Status in Young Women with Different Degrees of Adiposity. Nutrients, 2022, 14, 983.	4.1	4
115	Lack of Influence of the Androgen Receptor Gene CAG-Repeat Polymorphism on Clinical and Electrocardiographic Manifestations of the Brugada Syndrome in Man. Clinical Medicine Insights: Cardiology, 2012, 6, CMC.S10553.	1.8	3
116	Leptin modification in chronic myeloid leukemia patients treated with imatinib: An emerging effect of targeted therapy.. Leukemia Research Reports, 2013, 2, 58-60.	0.4	3
117	Aurora Kinases: New Molecular Targets for the Therapy of Aggressive Thyroid Cancers. , 2016, , .		3
118	Recent advances in precision medicine for the treatment of anaplastic thyroid cancer. Expert Review of Precision Medicine and Drug Development, 2019, 4, 37-49.	0.7	3
119	Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment. American Journal of Gastroenterology, 2001, 96, 2691-2699.	0.4	2
120	Immunoreactive beta-endorphin levels in cerebrospinal fluid of children with acute lymphoblastic leukemia: relationship with glucocorticoid therapy and neurological complications. Journal of Endocrinological Investigation, 1989, 12, 623-629.	3.3	1
121	Thyroid Autoantibodies and Breast Cancer. Asian Pacific Journal of Cancer Prevention, 2015, 15, 10999-10999.	1.2	1
122	Alternative strategies other than growth hormone for the treatment of immune diseases. Trends in Immunology, 2001, 22, 14-15.	6.8	0
123	Emerging Therapeutic Approaches for the Most Aggressive Epithelial Thyroid Cancers. , 2016, , .		0
124	Overexpression of the Components of the Plasminogen Activating System as Prognostic Factors in Human Thyroid Carcinoma. , 2010, , 445-458.		0
125	Plasminogen-Activating System. , 2014, , 1-5.		0
126	Plasminogen-Activating System. , 2016, , 3598-3602.		0